BRPI0409250A - composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar - Google Patents

composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar

Info

Publication number
BRPI0409250A
BRPI0409250A BRPI0409250-3A BRPI0409250A BRPI0409250A BR PI0409250 A BRPI0409250 A BR PI0409250A BR PI0409250 A BRPI0409250 A BR PI0409250A BR PI0409250 A BRPI0409250 A BR PI0409250A
Authority
BR
Brazil
Prior art keywords
sugar alcohol
solid pharmaceutical
pharmaceutical compositions
receptor agonist
agonist
Prior art date
Application number
BRPI0409250-3A
Other languages
English (en)
Inventor
Tomoyuki Oomura
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of BRPI0409250A publication Critical patent/BRPI0409250A/pt
Publication of BRPI0409250B1 publication Critical patent/BRPI0409250B1/pt
Publication of BRPI0409250B8 publication Critical patent/BRPI0409250B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS SóLIDAS COMPREENDENDO UM AGONISTA RECEPTOR DE S1P E UM áLCOOL DO AçúCAR". Uma composição farmacêutica sólida adequada para administração oral, compreendendo: (a) um agonista receptor de S1P; e (b) um álcool do açúcar.
BRPI0409250A 2003-04-08 2004-04-06 Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar BRPI0409250B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461,215 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (3)

Publication Number Publication Date
BRPI0409250A true BRPI0409250A (pt) 2006-03-28
BRPI0409250B1 BRPI0409250B1 (pt) 2017-07-11
BRPI0409250B8 BRPI0409250B8 (pt) 2022-01-18

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409250A BRPI0409250B8 (pt) 2003-04-08 2004-04-06 Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar

Country Status (42)

Country Link
US (11) US20060275357A1 (pt)
EP (5) EP2319502A1 (pt)
JP (3) JP5495467B2 (pt)
KR (3) KR101367574B1 (pt)
CN (2) CN1767819B (pt)
AR (3) AR043987A1 (pt)
AT (3) AT501681B1 (pt)
AU (1) AU2004228929B2 (pt)
BE (2) BE1015972A5 (pt)
BR (1) BRPI0409250B8 (pt)
CA (2) CA2521325C (pt)
CL (2) CL2004000745A1 (pt)
CY (3) CY1110260T1 (pt)
DE (4) DE602004017847D1 (pt)
DK (2) DK1613288T3 (pt)
EC (1) ECSP056090A (pt)
ES (3) ES2228282B1 (pt)
FR (2) FR2854073B1 (pt)
GB (1) GB2400318B (pt)
GR (1) GR1005052B (pt)
HK (3) HK1071685A1 (pt)
HR (3) HRP20050886B1 (pt)
HU (2) HUE028247T2 (pt)
IL (3) IL170888A (pt)
IS (2) IS2682B (pt)
IT (1) ITMI20040682A1 (pt)
LU (1) LU91867I2 (pt)
MA (1) MA27729A1 (pt)
MX (1) MXPA05010860A (pt)
MY (1) MY141249A (pt)
NO (4) NO329332B1 (pt)
NZ (3) NZ592339A (pt)
PE (5) PE20150676A1 (pt)
PL (2) PL2316431T3 (pt)
PT (1) PT1613288E (pt)
RU (5) RU2358716C2 (pt)
SG (1) SG175449A1 (pt)
SI (2) SI2316431T1 (pt)
TN (1) TNSN05256A1 (pt)
TW (1) TWI332847B (pt)
WO (1) WO2004089341A1 (pt)
ZA (1) ZA200507394B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
ES2357426T3 (es) * 2005-09-09 2011-04-26 Novartis Ag Tratamiento de enfermedades autoinmunes.
NZ595196A (en) 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL2041158T3 (pl) 2006-06-19 2013-08-30 Onyx Therapeutics Inc Peptydowe epoksyketony do hamowania proteasomu
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR102044064B1 (ko) * 2006-09-26 2019-11-12 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
HUE035990T2 (en) 2007-03-29 2018-05-28 Daiichi Sankyo Co Ltd Pharmaceutical preparation
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
KR101600098B1 (ko) * 2007-10-12 2016-03-04 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CA2735037C (en) * 2008-09-04 2016-07-12 Cargill Incorporated Tabletting of erythritol
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
BRPI0921533A2 (pt) 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
ES2643161T3 (es) * 2008-11-11 2017-11-21 Novartis Ag Formas cristalinas de HCL de fingolimod
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CN102256984B (zh) 2008-12-17 2014-09-03 第一三共株式会社 制备二胺衍生物的方法
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
BRPI1011804A2 (pt) * 2009-06-18 2018-02-27 Daiichi Sankyo Company, Limited composição farmacêutica com solubilidade melhorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2859553T3 (es) 2013-01-08 2021-10-04 Pathologica Llc Mitoguazona para el tratamiento de esclerosis múltiple progresiva
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
JP6294872B2 (ja) * 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
SK282225B6 (sk) 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
WO1998045249A1 (fr) * 1997-04-04 1998-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DE60208355T2 (de) 2001-03-26 2006-07-27 Novartis Ag 2-amino-propanol derivate
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
CN1329372C (zh) 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
US20220031609A1 (en) 2022-02-03
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
EP2008650A3 (en) 2011-04-27
RU2009105403A (ru) 2010-08-27
US20200237690A1 (en) 2020-07-30
ES2228282B1 (es) 2006-02-16
FR11C0036I1 (fr) 2011-10-14
KR101367574B1 (ko) 2014-02-25
HRP20100601B1 (hr) 2016-12-02
EP1613288A1 (en) 2006-01-11
PE20050396A1 (es) 2005-07-05
NO20055231D0 (no) 2005-11-07
NO20131287L (no) 2006-01-09
BRPI0409250B1 (pt) 2017-07-11
PE20130200A1 (es) 2013-03-09
MY141249A (en) 2010-03-31
RU2475236C2 (ru) 2013-02-20
FR2854073B1 (fr) 2008-03-14
ES2228282A1 (es) 2005-04-01
AT504853A2 (de) 2008-08-15
RU2358716C2 (ru) 2009-06-20
GR20040100121A (el) 2004-12-17
AT501681A1 (de) 2006-10-15
US20090203798A1 (en) 2009-08-13
US20190175527A1 (en) 2019-06-13
AU2004228929A1 (en) 2004-10-21
DK1613288T3 (da) 2009-03-23
CA2521325A1 (en) 2004-10-21
US20060275357A1 (en) 2006-12-07
NO329332B1 (no) 2010-09-27
AU2004228929B2 (en) 2008-02-07
NO2011016I1 (no) 2011-09-19
MXPA05010860A (es) 2006-05-25
LU91867I9 (pt) 2019-01-03
US20140011885A1 (en) 2014-01-09
PT1613288E (pt) 2009-02-25
EP2769713A1 (en) 2014-08-27
CY1117071T1 (el) 2017-04-05
KR20050121712A (ko) 2005-12-27
FR11C0036I2 (fr) 2023-12-29
RU2012148593A (ru) 2014-05-20
IL170888A (en) 2010-06-16
PE20150676A1 (es) 2015-05-17
DE602004017847D1 (de) 2009-01-02
IE20040246A1 (en) 2004-12-15
GB2400318A (en) 2004-10-13
BRPI0409250B8 (pt) 2022-01-18
CL2004000745A1 (es) 2005-02-11
US20110105620A1 (en) 2011-05-05
EP2008650A2 (en) 2008-12-31
DE202004021680U1 (de) 2010-04-22
ITMI20040682A1 (it) 2004-07-06
CY2011013I2 (el) 2014-04-09
HRP20050886A2 (en) 2006-11-30
GB2400318B (en) 2005-08-10
CN1767819A (zh) 2006-05-03
BE2011C030I2 (pt) 2023-03-07
ZA200507394B (en) 2007-03-28
RU2010147000A (ru) 2012-08-10
US20130108675A1 (en) 2013-05-02
HK1091114A1 (en) 2007-01-12
HRP20100600A2 (hr) 2011-03-31
JP2011006461A (ja) 2011-01-13
SI2316431T1 (sl) 2016-04-29
PE20131352A1 (es) 2013-11-14
DE122011100047I1 (de) 2011-12-15
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
JP5543298B2 (ja) 2014-07-09
JP2004307506A (ja) 2004-11-04
CN1767819B (zh) 2010-07-28
HK1155647A1 (en) 2012-05-25
IS8114A (is) 2005-11-01
RU2475237C2 (ru) 2013-02-20
HUS1100016I1 (hu) 2016-08-29
CY1110260T1 (el) 2014-04-09
SI1613288T1 (sl) 2009-04-30
CN101797241A (zh) 2010-08-11
TNSN05256A1 (en) 2007-07-10
IL242037A0 (en) 2015-11-30
US20080311188A1 (en) 2008-12-18
TW200503784A (en) 2005-02-01
AR078781A2 (es) 2011-11-30
WO2004089341A1 (en) 2004-10-21
NO335120B1 (no) 2014-09-22
JP2013177404A (ja) 2013-09-09
NZ542622A (en) 2009-01-31
CA2707750A1 (en) 2004-10-21
MA27729A1 (fr) 2006-01-02
JP5495467B2 (ja) 2014-05-21
GB0407819D0 (en) 2004-05-12
DK2316431T3 (en) 2016-01-11
EP2316431B1 (en) 2015-09-30
RU2010146697A (ru) 2012-05-27
US8324283B2 (en) 2012-12-04
NO20100250L (no) 2006-01-09
AR078782A2 (es) 2011-11-30
ES2320767T3 (es) 2009-05-28
NO334116B1 (no) 2013-12-16
ECSP056090A (es) 2006-03-01
EP2319502A1 (en) 2011-05-11
HUE028247T2 (en) 2016-12-28
ES2556947T3 (es) 2016-01-21
KR20120101148A (ko) 2012-09-12
DE102004016947A1 (de) 2004-10-21
CA2521325C (en) 2010-09-14
US20140255497A1 (en) 2014-09-11
EP1613288B1 (en) 2008-11-19
IL197578A0 (en) 2011-07-31
TWI332847B (en) 2010-11-11
PE20090743A1 (es) 2009-07-17
RU2005134173A (ru) 2006-09-10
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AT501681B1 (de) 2012-04-15
HRP20100601A2 (hr) 2011-03-31
HRP20050886B1 (en) 2011-01-31
GR1005052B (el) 2005-11-30
IL197578A (en) 2015-10-29
NZ592339A (en) 2012-09-28
NZ586280A (en) 2011-12-22
FR2854073A1 (fr) 2004-10-29
ATE414508T1 (de) 2008-12-15
IS8885A (is) 2010-02-25
LU91867I2 (fr) 2011-11-08
SG175449A1 (en) 2011-11-28
CY2011013I1 (el) 2014-04-09
IS2682B (is) 2010-10-15
NO2011016I2 (no) 2012-08-27
PL1613288T3 (pl) 2009-07-31
KR20110005320A (ko) 2011-01-17
AR043987A1 (es) 2005-08-17
US20170290787A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
BRPI0409250A (pt) composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20064808L (no) Orale matrixformuleringer med licarbazepin
BRPI0413676A (pt) composto, e, composição farmacêutica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
GB2407498B (en) Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
WO2005037247A3 (en) Oral matrix formulations of doxazosin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA:INT.CI. A61K31/135 " "A61K31/137 "31/00

Ipc: A61K 31/135 (2011.01), A61K 31/137 (2011.01), A61K

Free format text: PARA:INT.CI. A61K31/135; A61K31/137; A61K45/00; A61K45/06; A61K47/12; A61K47/26; A61K9/20; A61K9/36; A61K9/48; A61K9/62; A61P29/00; A61P31/00; A61P31/12; A61P37/00; A61P37/02; A61P37/06; A61K31/135; A61K31/137; A61K45/00; A61K47/12; A61K47/26; A61K9/20; A61K9/30; A61K9/48; A61K9/52; A61P29/00; A61P31/00; A61P37/00

Ipc: A61K 31/135 (2011.01), A61K 31/137 (2011.01), A61K

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO PARAGRAFO 2O, ART.1O DA RESOLUCAO 080/13.

B65X Notification of requirement for priority examination of patent application
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: NOVARTIS AG (CH) , MITSUBISHI PHARMA CORPORATION (

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20130072954/RJ, DE 29/08/2013, E NECESSARIO APRESENTAR DOCUMENTACAO QUE EVIDENCIE A ALTERACAO DE NOME SOLICITADA, POIS OS DOCUMENTOS APRESENTADOS MOSTRAM UMA INCORPORACAO POR ABSORCAO.

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH) , MITSUBISHI TANABE PHARMA CORPOR

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: REFERENTE AO DESPACHO 15.24 PUBLICADO NA RPI NO 2251 DE 25/02/2014.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO NPRJ020130078305 DE 25/09/2013, COM BASE NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE HOUVE A DESISTENCIA DA SOLICITACAO DE EXAME PRIORITARIO ATRAVES DOS PROTOCOLOS RJ 860140048882 DE 10/04/2014 E RJ 860140173031 DE 15/10/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B25E Requested change of name of applicant rejected
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent
B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001988/2018-52 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0005369-50.2018.4.02.0000 AGRAVANTE: EMS S.A. AGRAVADO: INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL, NOVARTIS AG E MITSUBISHI TANABE PHARMA DECISAO: ANTE O EXPOSTO, DEFIRO A TUTELA DE URGENCIA RECURSAL, PARA SUSPENDER OS EFEITOS DA PI0409250-3, INTER PARTES, NOS TERMOS DO ART. 932 II, DO CPC DE 2015, ATE A DECISAO FINAL DESTE AGRAVO DE INSTRUMENTO.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001988/2018-52 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO:NO: 0219305-21.2017.4.02.5101 AUTOR: SEM S/AREU: NOVARTIS AG E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: DEFIRO O REQUERIMENTO DE TUTELA DE URGENCIA PARA SUSPENDER OS EFEITOS DA PATENTE PI 0409250-3 ENTRE AS PARTES.AFASTO, POR INCOMPETENCIA, A ANALISE DOS REQUERIMENTOS DE QUE AS EMPRESAS RES OU OUTRAS DE SEU GRUPO ECONOMICO DEIXEM DE OBSTAR AS ATIVIDADES DA DEMANDANTE, E QUE A AUTORA NAO SEJA TOLHIDA POR TERCEIROS DE VIR A COMERCIALIZAR SEU MEDICAMENTO. A ANALISE DESSAS QUESTOES DEVE SER FEITA EM AMBITO DA JUSTICA ESTADUAL, QUE DEVE PASSAR A CONSIDERAR AGORA A SUSPE

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.001988/2018-52 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL DO RIO DE JANEIRO PROCEDIMENTO COMUM NO 0219305-21.2017.4.02.5101/RJ NUP: 00408.033558/2019-15 AUTOR: EMS S/A REU: NOVARTIS AG REU: INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO:DIANTE DO EXPOSTO, JULGO PROCEDENTE O PEDIDO, PARA DECLARAR A NULIDADE DA PATENTE PI0409250-3, NOS TERMOS DO ART. 487, I, DO CPC. CONCEDO A TUTELA PROVISORIA DE URGENCIA PARA DETERMINAR A SUSPENSAO DOS EFEITOS DA PI0409250-3, ATE O TRANSITO EM JULGADO DA SENTENCA, PELOS FUNDAMENTOS ACIMA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.